

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2019 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:
  - i) Alivira Animal Health Australia Pty Ltd;
  - ii) Alivira Animal Health Limited, Ireland;
  - iii) Alivira Animal Health Limited, India;
  - iv) Alivira Saude Animal Brasil Participacoes Ltda;
  - v) Alivira UA Limited;
  - vi) Alivira France;
  - vii) Alivira Italia S.R.L.
  - viii) Bremer Pharma GMBH;
  - ix) Comercial Vila Veterinaria de Lleida S.L;
  - x) Elysian Life Sciences Private Limited;
  - xi) Evance Saude Animal Ltda
  - xii) Fendigo BV;
  - xiii) Fendigo SA;
  - xiv) Interchange Veterinária Indústria E Comércio Ltda;
  - xv) Laboratorios Karizoo, S.A;
  - xvi) Laboratorios Karizoo, S.A. De C.V. (Mexico);
  - xvii) N-Vet AB;
  - xviii) Phytotherapeutic Solutions S.L;
  - xix) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
  - xx) SeQuent Antibiotics Private Limited;
  - xxi) SeQuent Pharmaceuticals Private Limited;
  - xxii) SeQuent Research Limited;
  - xxiii) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;
  - xxiv) Vila Viña Participacions S.L.

aw


5. Based on our review conducted as stated above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial results of thirteen subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 17,715.74 lakhs for the quarter ended June 30, 2019, total net profit after tax of Rs. 1,367.03 lakhs for the quarter ended June 30, 2019 and total comprehensive income of Rs. 1,367.03 lakhs for the quarter ended June 30, 2019, as considered in the Statement. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results includes the interim financial results of ten subsidiaries which have not been reviewed by their auditors, whose financial results reflect total revenue of Rs. 846.82 lakhs for the quarter ended June 30, 2019, total loss after tax of Rs. 121.09 lakhs for the quarter ended June 30, 2019 and Total comprehensive loss of Rs. 120.24 lakhs for the quarter ended June 30, 2019, as considered in the Statement. According to the information and explanations given to us by the Management, these financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial results certified by the Management.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Sathya P. Koushik**  
Partner  
(Membership No. 206920)

Bengaluru, July 31, 2019  
SPK/JKS/DSS/2019  
(UDIN: 19206920AAAACZ8451)

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2019**

(Rs. in Lakhs)

	Particulars	3 months ended 30-Jun-2019	Preceding 3 months ended 31-Mar-2019	Corresponding 3 months ended in the previous year 30-Jun-2018	Previous year ended 31-Mar-2019
		Unaudited	Audited (Refer Note 5)	Unaudited	Audited
I	Revenue from operations	27,801.70	28,190.30	23,515.20	1,03,930.70
II	Other income	131.20	242.70	181.40	867.20
III	<b>Total income (I+II)</b>	<b>27,932.90</b>	<b>28,433.00</b>	<b>23,696.60</b>	<b>1,04,797.90</b>
IV	<b>Expenses</b>				
	(a) Cost of materials consumed	12,002.70	15,222.00	10,507.60	45,387.10
	(b) Purchases of stock-in-trade	2,227.40	1,538.20	3,354.70	11,664.40
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	81.20	(2,341.70)	(1,211.20)	(2,750.30)
	(d) Employee benefits expense	3,971.40	3,947.00	3,513.60	14,594.90
	(e) Finance costs	894.50	890.20	778.30	3,280.20
	(f) Depreciation and amortisation expense	1,201.20	1,092.20	963.80	4,192.00
	(g) Other expenses	5,674.80	5,924.90	5,098.90	22,541.20
	<b>Total expenses</b>	<b>26,053.20</b>	<b>26,272.80</b>	<b>23,005.70</b>	<b>98,909.50</b>
V	<b>Profit before tax (III-IV)</b>	<b>1,879.70</b>	<b>2,160.20</b>	<b>690.90</b>	<b>5,888.40</b>
VI	<b>Tax expense</b>				
	(a) Current tax	391.10	133.00	340.70	1,419.90
	(b) MAT credit entitlement	(60.30)	201.70	(84.80)	(366.40)
	(c) Deferred tax	19.00	(128.70)	(13.00)	964.70
	(d) Current tax of prior period reversed	0.30	(178.50)	-	(1,817.50)
	<b>Total tax expenses</b>	<b>350.10</b>	<b>27.50</b>	<b>242.90</b>	<b>200.70</b>
VII	<b>Profit for the period after tax (V-VI)</b>	<b>1,529.60</b>	<b>2,132.70</b>	<b>448.00</b>	<b>5,687.70</b>
VIII	<b>Other comprehensive income</b>				
	<b>Items that will not be reclassified to profit or loss</b>				
	(a) Re-measurement gain / (loss) on defined benefits plans	(0.40)	(68.70)	(5.00)	(43.30)
	(b) Fair value gain / (loss) from investment in equity instruments (net)	(2,281.20)	974.60	(7,711.90)	(4,217.50)
	<b>Items that may be reclassified to profit or loss</b>				
	(a) Exchange differences on translation of foreign operations (net)	(257.00)	590.42	(136.56)	546.51
	(b) Exchange differences on net investment in foreign operations (net)	(62.10)	(1,279.90)	355.51	(1,651.12)
	<b>Total other comprehensive income for the period</b>	<b>(2,600.70)</b>	<b>216.42</b>	<b>(7,497.95)</b>	<b>(5,365.41)</b>
IX	<b>Total comprehensive income for the period (VII+VIII)</b>	<b>(1,071.10)</b>	<b>2,349.12</b>	<b>(7,049.95)</b>	<b>322.29</b>
	<b>Profit for the period attributable to:</b>				
	- Owners of the Company	1,145.70	1,712.40	328.00	4,866.00
	- Non-controlling interest	383.90	420.30	120.00	821.70
	<b>Other comprehensive income for the period attributable to:</b>				
	- Owners of the Company	(2,575.20)	344.48	(7,433.45)	(5,071.65)
	- Non-controlling interest	(25.50)	(128.06)	(64.50)	(293.76)
	<b>Total comprehensive income for the period attributable to:</b>				
	- Owners of the Company	(1,429.50)	2,056.88	(7,105.45)	(205.65)
	- Non-controlling interest	358.40	292.24	55.50	527.94
	<b>Earnings per equity share: (face value of Rs. 2 each) (not annualised)</b>				
	(1) Basic ( in Rs.)	0.47	0.71	0.14	2.00
	(2) Diluted (in Rs.)	0.47	0.70	0.13	1.99
	<b>See accompanying notes to the financial results</b>				



# Sequent

Proven Ability in Life Sciences  
SEQUENT SCIENTIFIC LIMITED

**Notes:**

1. The unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31 July 2019.
2. The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

**3. Information on Standalone Results:**

*(Rs. in Lakhs)*

Particulars	3 months ended 30-Jun-2019	Preceding 3 months ended 31-Mar-2019	Corresponding 3 months ended in the previous year 30-Jun-2018	Previous year ended 31-Mar-2019
	Unaudited	Audited (Refer Note 5)	Unaudited	Audited
Revenue from operations	5,207.50	5,700.80	2,628.50	16,767.70
Profit before tax	142.30	0.50	261.90	620.30
Profit for the period after tax	142.30	138.84	261.90	758.64
Total comprehensive income	(2,137.80)	1,112.74	(7,459.00)	(3,454.46)

4. Effective 01 April 2019, the Group applied Ind AS 116 - "Leases" to applicable lease contracts existing as on 01 April 2019. The Group has used the modified retrospective method prescribed under Ind AS 116 and accordingly, the comparative numbers have not been retrospectively adjusted. The application of Ind AS 116 did not have a significant impact on the profit and earnings per share for the quarter ended 30 June 2019.

5. The above results includes the results for the quarter ended 31 March 2019 being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.

6. During the previous year, SeQuent Antibiotics Private Limited and SeQuent Pharmaceuticals Private Limited (wholly owned subsidiaries) have applied for strike off their name from register of Registrar of Company - Bengaluru under fast track exit scheme of Ministry of Corporate Affairs. The Registrar of Company vide letter dated 26 July 2019 have removed their name from Register of Companies and the said companies are dissolved.

7. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.



For Sequent Scientific Limited

Manish

**Manish Gupta**  
Managing Director

Place : Thane

Date : 31 July 2019

b

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE  
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
SEQUENT SCIENTIFIC LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company"), for the quarter ended June 30, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Sathya P. Koushik**  
Partner  
(Membership No. 206920)

Bengaluru, July 31, 2019  
SPK/JKS/DSS/2019  
(UDIN: 19206920AAAACY6921)

**Sequent**  
Proven Ability in Life Sciences  
**SEQUENT SCIENTIFIC LIMITED**

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2019**

(Rs. in Lakhs)

	Particulars	3 months ended 30-Jun-2019	Preceding 3 months ended 31-Mar-2019	Corresponding 3 months ended in previous period 30-Jun-2018	Previous year ended 31-Mar-19
		UNAUDITED	AUDITED (Refer note 3)	UNAUDITED	AUDITED
I	Revenue from operations	5,207.50	5,700.80	2,628.50	16,767.70
II	Other income	203.10	157.90	435.60	1,352.50
III	<b>Total income (I+II)</b>	<b>5,410.60</b>	<b>5,858.70</b>	<b>3,064.10</b>	<b>18,120.20</b>
IV	<b>Expenses</b>				
	(a) Cost of materials consumed	2,553.04	2,247.42	916.10	7,733.92
	(b) Purchases of stock-in-trade	62.16	195.68	1,026.60	2,023.18
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	203.40	799.80	(160.80)	(294.90)
	(d) Conversion and processing charges	894.00	890.30	398.00	3,180.40
	(e) Employee benefits expense	349.50	352.80	157.50	1,096.90
	(f) Finance costs	142.00	182.60	1.30	322.00
	(g) Depreciation and amortisation expense	223.70	230.50	87.70	726.40
	(h) Other expenses	840.50	959.10	375.80	2,712.00
	<b>Total expenses</b>	<b>5,268.30</b>	<b>5,858.20</b>	<b>2,802.20</b>	<b>17,499.90</b>
V	<b>Profit before tax (III-IV)</b>	<b>142.30</b>	<b>0.50</b>	<b>261.90</b>	<b>620.30</b>
VI	<b>Tax expense</b>				
	(a) Current tax	29.29	0.04	55.60	132.94
	(b) MAT credit entitlement	(29.29)	(0.04)	(55.60)	(132.94)
	(c) Current tax of prior period reversed	-	(138.34)	-	(138.34)
	<b>Total tax expenses</b>	<b>-</b>	<b>(138.34)</b>	<b>-</b>	<b>(138.34)</b>
VII	<b>Profit for the period after tax (V-VI)</b>	<b>142.30</b>	<b>138.84</b>	<b>261.90</b>	<b>758.64</b>
VIII	<b>Other comprehensive income</b>				
	<b>Items that will not be reclassified to profit or loss</b>				
	(a) Re-measurements gain / (loss) on defined benefits plans	1.10	(0.70)	(9.00)	4.40
	(b) Fair value gain / (loss) from investment in equity instruments (net)	(2,281.20)	974.60	(7,711.90)	(4,217.50)
	<b>Total other comprehensive income for the period</b>	<b>(2,280.10)</b>	<b>973.90</b>	<b>(7,720.90)</b>	<b>(4,213.10)</b>
IX	<b>Total comprehensive (loss)/income for the period (VII+VIII)</b>	<b>(2,137.80)</b>	<b>1,112.74</b>	<b>(7,459.00)</b>	<b>(3,454.46)</b>
	<b>Earnings per equity share: (Face value of Rs. 2 each) (not-annualised)</b>				
	(1) Basic ( in Rs.)	0.06	0.06	0.11	0.31
	(2) Diluted (in Rs.)	0.06	0.06	0.11	0.31
	<b>See accompanying notes to financial results</b>				



**Sequent**  
Proven Ability In Life Sciences  
**SEQUENT SCIENTIFIC LIMITED**

**Notes:**

- 1 The unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31 July 2019.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 The above results includes the results for the quarter ended 31 March 2019 being the balancing figure between audited figures in respect of the full financial year and the recast published year to date figures up to the third quarter of the previous financial year.
- 4 Effective 01 April 2019, the Company applied Ind AS 116 - "Leases" to applicable lease contracts existing as on 01 April 2019. The Company has used the modified retrospective method prescribed under Ind AS 116 and accordingly, the comparative numbers have not been retrospectively adjusted. The application of Ind AS 116 did not have a significant impact on the profit and earnings per share for the quarter ended 30 June, 2019.
- 5 During the previous year, SeQuent Antibiotics Private Limited and SeQuent Pharmaceuticals Private Limited (Wholly-owned subsidiaries) have applied for strike off their name from register of Registrar of Company - Bengaluru under fast track exit scheme of Ministry of Corporate Affairs. The Registrar of Company vide letter dated 26 July 2019 have removed their name from Register of Companies and the said companies are dissolved.
- 6 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited



*Manish*  
Manish Gupta  
Managing Director

Place : Thane  
Date: 31 July 2019

h